JP5797554B2 - 新規レチノイド誘導因子およびその使用 - Google Patents

新規レチノイド誘導因子およびその使用 Download PDF

Info

Publication number
JP5797554B2
JP5797554B2 JP2011513442A JP2011513442A JP5797554B2 JP 5797554 B2 JP5797554 B2 JP 5797554B2 JP 2011513442 A JP2011513442 A JP 2011513442A JP 2011513442 A JP2011513442 A JP 2011513442A JP 5797554 B2 JP5797554 B2 JP 5797554B2
Authority
JP
Japan
Prior art keywords
rinf
cells
cys
arg
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011513442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525352A5 (enExample
JP2011525352A (ja
Inventor
ヨハン、アル．リレハウグ
フレデリック、ペンディノ
Original Assignee
ベルゲン・テクノロジオーヴァーフォリング・アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベルゲン・テクノロジオーヴァーフォリング・アクティーゼルスカブ filed Critical ベルゲン・テクノロジオーヴァーフォリング・アクティーゼルスカブ
Publication of JP2011525352A publication Critical patent/JP2011525352A/ja
Publication of JP2011525352A5 publication Critical patent/JP2011525352A5/ja
Application granted granted Critical
Publication of JP5797554B2 publication Critical patent/JP5797554B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011513442A 2008-06-09 2009-06-09 新規レチノイド誘導因子およびその使用 Expired - Fee Related JP5797554B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NO20082550 2008-06-09
NO20082550 2008-06-09
NO20090358A NO20090358L (no) 2008-06-09 2009-01-23 Retinoid-induserbar faktor, og anvendelse derav
NO20090358 2009-01-23
PCT/NO2009/000214 WO2009151337A2 (en) 2008-06-09 2009-06-09 Novel retinoid inducible factor and uses thereof

Publications (3)

Publication Number Publication Date
JP2011525352A JP2011525352A (ja) 2011-09-22
JP2011525352A5 JP2011525352A5 (enExample) 2012-07-19
JP5797554B2 true JP5797554B2 (ja) 2015-10-21

Family

ID=41328567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011513442A Expired - Fee Related JP5797554B2 (ja) 2008-06-09 2009-06-09 新規レチノイド誘導因子およびその使用

Country Status (7)

Country Link
US (1) US20120003181A1 (enExample)
EP (1) EP2321343B1 (enExample)
JP (1) JP5797554B2 (enExample)
DK (1) DK2321343T3 (enExample)
ES (1) ES2542866T3 (enExample)
NO (2) NO20090358L (enExample)
WO (1) WO2009151337A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616540T3 (es) 2010-07-21 2017-06-13 Bergen Teknologioverføring As Métodos para determinar un pronóstico de supervivencia para un paciente con leucemia
KR101721028B1 (ko) * 2014-02-12 2017-03-29 연세대학교 산학협력단 상처 치유 촉진용 조성물
WO2024074713A1 (en) * 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
CN116004829A (zh) * 2023-01-04 2023-04-25 上海良福生物科技有限公司 一种notch1的胞内活化结构域（nicd1）调节剂及其应用
CN119060944B (zh) * 2023-05-31 2025-11-11 士泽生物医药（苏州）有限公司 利用粒细胞集落刺激因子诱导心肌细胞分化成熟的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6906800A (en) * 1999-08-17 2001-03-13 Incyte Genomics, Inc. Membrane associated proteins
CA2625403A1 (en) * 2005-10-17 2007-04-26 Institute For System Biology Tissue-and serum-derived glycoproteins and methods of their use

Also Published As

Publication number Publication date
WO2009151337A3 (en) 2010-07-08
EP2321343B1 (en) 2015-06-03
WO2009151337A2 (en) 2009-12-17
NO20090358L (no) 2009-12-10
NO20100815A1 (no) 2011-03-09
ES2542866T3 (es) 2015-08-12
EP2321343A2 (en) 2011-05-18
DK2321343T3 (en) 2015-08-24
US20120003181A1 (en) 2012-01-05
JP2011525352A (ja) 2011-09-22

Similar Documents

Publication Publication Date Title
AU2017266686B2 (en) Markers selectively deregulated in tumor-infiltrating regulatory T cells
Guerzoni et al. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells
WO2021247540A1 (en) Methods for modulating mhc-i expression and immunotherapy uses thereof
Pendino et al. Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis
WO2015077058A2 (en) Compositions and methods for selecting a treatment for b-cell neoplasias
JP5797554B2 (ja) 新規レチノイド誘導因子およびその使用
Bondeva et al. Advanced glycation end-products suppress neuropilin-1 expression in podocytes
Le et al. Characterization of the ETO and AML1–ETO proteins involved in the 8; 21 translocation in acute myelogenous leukemia
KR102848030B1 (ko) Dctn1 단백질과 ret 단백질과의 융합 단백질
US9091696B2 (en) Modulation of NR2F6 and methods and uses thereof
Li et al. Gene profiling of Frizzled-1 and Frizzled-2 signaling: expression of G-protein-coupled receptor chimeras in mouse F9 teratocarcinoma embryonal cells
JP2010057497A (ja) 抗癌剤の開発および癌の診断のための、腫瘍の発生に関与することが同定されたマウスゲノム領域の使用
WO2004016317A1 (en) Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
EP1379651A2 (en) Human genes and gene expression products isolated from human prostate
US20250381241A1 (en) Methods and compositions to modulate riok2
US20250320501A1 (en) Palmitoylation of the alternative amino terminus of the btk-c isoform controls subcellular distribution and signaling
US20140235481A1 (en) Cancer biomarker and methods of use thereof
EP4440594A2 (en) Methods and compositions to modulate riok2
Pasalic The four and a half LIM domain protein 2 (FHL2) interacts with CALM and is highly expressed in acute myeloid leukemia (AML) with complex aberrant karyotypes
Kerley-Hamilton The importance of p53-dependent transcriptional responses in the differentiation and curability of human embryonal carcinoma
Akkawi et al. Rapid Screening of BCR/ABL Fusion Transcripts in Philadelphia Chromosome Positive Leukemias by Multiplex RT-PCR
Gruber et al. Molecular genetics of acute myeloid leukemia
Peters Identification of PEA3 Target Genes in Human Cells
Fröhlich Archangelo Functional characterization of the CATS gene with respect to its role in normal hematopoiesis and in leukemia
Brennand Analysis of deregulation of expression of HNRNPA2B1 in primary lung cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140306

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150507

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150706

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150724

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150819

R150 Certificate of patent or registration of utility model

Ref document number: 5797554

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees